ADAMTS13 and thrombotic thrombocytopenic purpura: Congenital TTP patients receiving treatment with regular prophylactic donor plasma infusions to replace ADAMTS13 report symptomatic relief with commencement of prophylaxis and also have a significantly reduced incidence of stroke (2% vs. 17%) compared to those not receiving prophylaxis [17].